U.S. markets open in 2 hours 50 minutes
  • S&P Futures

    3,983.25
    +6.50 (+0.16%)
     
  • Dow Futures

    32,148.00
    +72.00 (+0.22%)
     
  • Nasdaq Futures

    11,927.50
    -14.75 (-0.12%)
     
  • Russell 2000 Futures

    1,803.90
    +7.10 (+0.40%)
     
  • Crude Oil

    111.39
    +1.06 (+0.96%)
     
  • Gold

    1,844.10
    -2.20 (-0.12%)
     
  • Silver

    21.83
    -0.04 (-0.18%)
     
  • EUR/USD

    1.0717
    +0.0032 (+0.30%)
     
  • 10-Yr Bond

    2.7490
    0.0000 (0.00%)
     
  • Vix

    28.29
    -1.16 (-3.94%)
     
  • GBP/USD

    1.2611
    +0.0033 (+0.26%)
     
  • USD/JPY

    126.5890
    -0.6520 (-0.51%)
     
  • BTC-USD

    29,167.95
    -556.88 (-1.87%)
     
  • CMC Crypto 200

    639.19
    -31.81 (-4.74%)
     
  • FTSE 100

    7,532.96
    +10.21 (+0.14%)
     
  • Nikkei 225

    26,604.84
    -72.96 (-0.27%)
     

Arcturus Therapeutics' COVID-19 Booster Clinical Trial Show Encouraging Neutralizing Antibody Responses

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) has announced updated data Phase 1/2 booster trial of ARCT-154 and ARCT-165, its investigational, self-amplifying mRNA COVID-19 vaccine candidates targeting the variants of concern.

  • Data from the Phase 1/2 booster trial show that both ARCT-154 and ARCT-165, when administered as low-dose (5 mcg) boosters at least five months after Pfizer Inc's (NYSE: PFE) - BioNTech SE's (NASDAQ: BNTX) Comirnaty immunization, demonstrated robust antibody responses.

  • Related: Arcturus Shares Shoot Higher After Additional Data From COVID-19 Vaccine Programs.

  • Neutralizing antibody concentrations were maintained between 15 and 29 days post-administration.

  • These results are expected to support further clinical development of these candidates as booster vaccines.

  • Price Action: ARCT shares are down 6.47% at $23.00 during the premarket session on Monday's last check.

See more from Benzinga

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.